Nadir Prolactin–guided Individualized Cabergoline Therapy Achieves Durable Remission and Safe Pregnancy in Prolactinomas

Clicks: 10
ID: 330781
2026
Free PDF
Article Quality & Performance Metrics
Overall Quality
Not rated
Combines reader engagement with the AI quality analysis. This article has not been analysed, so there is no overall score — reader engagement is measured and shown alongside.
AI Quality Assessment
Not analyzed
Readership in this journal
Emerging

Ranked #336 of 409 articles by views in the journal of clinical endocrinology & metabolism

Most read Least read

Bar heights use a square-root scale. Only the 120 most-read articles are drawn; the journal has 409 in total.

Mint this article as an NFT
Not yet minted

Create a permanent, verifiable on-chain record of this article on the Scimatic Network. The NFT is held in your Journament account, and you can withdraw it to your own wallet at any time.

5 SUSD one-off · no wallet required
Sign in to mint
Abstract
CONTEXT: Achieving durable prolactinoma remission while preserving safe pregnancy remains a central unmet goal of cabergoline therapy. OBJECTIVE: To prospectively evaluate individualized-dose cabergoline therapy for safe pregnancy, remission, and dosing optimization. METHODS: Women with 310 prolactinomas comprised 97 bromocriptine (BC)-resistant, 93 BC-intolerant, and 120 naïve patients, harboring 56 large macroprolactinomas (≥20 mm), 80 small macroprolactinomas (≥10 mm), and 174 microprolactinomas. Cabergoline dosing was individualized to maintain nadir prolactin within the lowest achievable normal range. In 129 macroprolactinomas and 19 microprolactinomas at risk of gestational enlargement, medical debulking prophylactically restored the optic-pituitary (O-P) distance to >5.0 mm before conception. Cabergoline was discontinued immediately after conception. RESULTS: Treatment achieved 100% biochemical normalization; 84-100% prepregnancy tumor debulking; 365 uneventful pregnancies in 294 patients (95%); no symptomatic tumor enlargement during pregnancy; and 72% postpartum remission overall (naïve 82%, BC-resistant 70%, BC-intolerant 61%; microprolactinomas 73%, macroprolactinomas 72%). Responder frequency was subtype-specific across 0.25-9.0 mg/week doses with distinct ED50 values ranging from 0.66 in BC-intolerant to 3.71 in BC-resistant patients. AIC-based multivariate analysis identified nadir prolactin-markedly lower in nonvisible than residual prolactinomas-as the dominant determinant of tumor disappearance. No cardiac valvulopathy or impulse control disorders were observed on longitudinal follow-up. CONCLUSION: Despite marked ED50 heterogeneity, nadir prolactin-guided individualized-dose cabergoline therapy safely achieved durable remission with excellent pregnancy outcomes. These findings establish a clinically actionable, outcome-directed framework that prospectively integrates endocrine normalization, anatomical risk reduction, and tumor eradication, rendering durable remission and safe pregnancy realistically achievable therapeutic objectives in prolactinomas.
Reference Key
openalex_W7215052484 Use this key to autocite in the manuscript while using SciMatic Manuscript Manager or Thesis Manager
Authors Nobuhiro Miki, Masami Ono, Shun‐ichiro Izumi, Tomokatsu Hori, Kayoko Abe, Takakazu Kawamata
Journal the journal of clinical endocrinology & metabolism
Year 2026
DOI
10.1210/clinem/dgag406
URL
https://doi.org/10.1210/clinem/dgag406
Keywords Keywords not found

Citations

No citations found. To add a citation, contact the admin at info@scimatic.org

Comments

No comments yet. Be the first to comment on this article.